Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00034216 · ClinicalTrials.gov registry record

Collection of Blood From Patients With Cancer

A clinical trial of Breast Cancer and Prostate Cancer, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
1,750
Enrollment target
1
Study location

NCT00034216 is a study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,750 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00034216, a study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
1,750 participants
Enrollment target
1
Study location

Study Summary

This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. ...

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 1,750 participants
Start Date 2002-07-16

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00034216

The ClinicalTrials.gov registry entry for NCT00034216 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,750 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (38% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT00034216 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00034216 about?

NCT00034216 is a clinical study titled "Collection of Blood From Patients With Cancer". This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have abou...

What is the current status of trial NCT00034216?

This trial is currently recruiting. The enrollment target is 1,750 participants. The study started on 2002-07-16.

What conditions does trial NCT00034216 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Liver Cancer.

Who is sponsoring clinical trial NCT00034216?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00034216 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.